S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
BREAKING: Tiny biotech successfully treats blindness (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
BREAKING: Tiny biotech successfully treats blindness (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
BREAKING: Tiny biotech successfully treats blindness (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
BREAKING: Tiny biotech successfully treats blindness (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:ABOS

Acumen Pharmaceuticals (ABOS) Stock Forecast, Price & News

$4.93
-0.01 (-0.20%)
(As of 05/31/2023 ET)
Compare
Today's Range
$4.77
$4.99
50-Day Range
$3.59
$6.59
52-Week Range
$3.16
$10.97
Volume
64,973 shs
Average Volume
136,882 shs
Market Capitalization
$202.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.75

Acumen Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
219.5% Upside
$15.75 Price Target
Short Interest
Healthy
0.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of Acumen Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.30) to ($1.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

331st out of 1,006 stocks

Biological Products, Except Diagnostic Industry

44th out of 167 stocks


ABOS stock logo

About Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
WARNING to all American Investors
China's sneaky plan could wipe out your retirement - in a single morning. Learn how to protect yourself here>>>
BTIG Remains a Buy on Acumen Pharmaceuticals (ABOS)
See More Headlines
Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Company Calendar

Last Earnings
3/27/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABOS
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.75
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+219.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-42,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.44 million
Book Value
$4.37 per share

Miscellaneous

Free Float
39,097,000
Market Cap
$202.28 million
Optionable
Not Optionable
Beta
-1.56

Key Executives

  • Mr. Daniel J. O'Connell M.B.A. (Age 52)
    CEO, Pres & Director
    Comp: $801.62k
  • Mr. Matt Zuga
    CFO, Chief Bus. Officer & Corp. Sec.
  • Dr. Eric Siemers M.D. (Age 68)
    Chief Medical Officer
    Comp: $460.64k
  • Mr. Russell Barton M.S. (Age 64)
    Chief Operating Officer
  • Mr. Derek M. Meisner Esq. (Age 52)
    J.D., Chief Legal Officer
  • Ms. Robyn Moxon M.A.
    Mang. of Corp. & Clinical Communications
  • Ms. Julie Bockenstette
    Exec. VP & Head of HR
  • Ms. Siew Tin Gan M.S.
    Assistant VP & Head of Clinical Operations
  • Ms. Janice Hitchcock
    VP & Head of Regulatory Affairs
  • Ms. Liean Schenck M.S.
    VP & Head of CMC













ABOS Stock - Frequently Asked Questions

Should I buy or sell Acumen Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABOS shares.
View ABOS analyst ratings
or view top-rated stocks.

What is Acumen Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price targets for Acumen Pharmaceuticals' shares. Their ABOS share price forecasts range from $13.00 to $22.00. On average, they anticipate the company's share price to reach $15.75 in the next year. This suggests a possible upside of 219.5% from the stock's current price.
View analysts price targets for ABOS
or view top-rated stocks among Wall Street analysts.

How have ABOS shares performed in 2023?

Acumen Pharmaceuticals' stock was trading at $5.40 at the beginning of the year. Since then, ABOS shares have decreased by 8.7% and is now trading at $4.93.
View the best growth stocks for 2023 here
.

Are investors shorting Acumen Pharmaceuticals?

Acumen Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 159,800 shares, a drop of 26.3% from the April 30th total of 216,800 shares. Based on an average daily trading volume, of 168,700 shares, the short-interest ratio is presently 0.9 days. Currently, 0.6% of the shares of the company are short sold.
View Acumen Pharmaceuticals' Short Interest
.

When is Acumen Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ABOS earnings forecast
.

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) released its earnings results on Monday, March, 27th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04.

When did Acumen Pharmaceuticals IPO?

(ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.

What is Acumen Pharmaceuticals' stock symbol?

Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."

Who are Acumen Pharmaceuticals' major shareholders?

Acumen Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Great Point Partners LLC (2.56%), BlackRock Inc. (1.64%), Commodore Capital LP (0.98%), Hudson Bay Capital Management LP (0.87%), Guardian Point Capital LP (0.32%) and Jane Street Group LLC (0.18%). Insiders that own company stock include John A Stalfort III, Marc Benioff, Nathan B Fountain, Paul B Manning and Sands Capital Global Venture F.
View institutional ownership trends
.

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acumen Pharmaceuticals' stock price today?

One share of ABOS stock can currently be purchased for approximately $4.93.

How much money does Acumen Pharmaceuticals make?

Acumen Pharmaceuticals (NASDAQ:ABOS) has a market capitalization of $202.28 million and generates $1.44 million in revenue each year. The company earns $-42,860,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How can I contact Acumen Pharmaceuticals?

The official website for the company is www.acumenpharm.com. The company can be reached via phone at 434-297-1000 or via email at investors@acumenpharm.com.

This page (NASDAQ:ABOS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -